➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Merck
Mallinckrodt
AstraZeneca
Dow

Last Updated: October 20, 2021

DrugPatentWatch Database Preview

Ferumoxytol - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic sources for ferumoxytol and what is the scope of patent protection?

Ferumoxytol is the generic ingredient in two branded drugs marketed by Covis and Sandoz Inc, and is included in two NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ferumoxytol has thirteen patent family members in ten countries.

There is one drug master file entry for ferumoxytol. Two suppliers are listed for this compound.

Recent Clinical Trials for ferumoxytol

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Holden Comprehensive Cancer CenterPhase 1
Bryan AllenPhase 1
University of Wisconsin, MadisonEarly Phase 1

See all ferumoxytol clinical trials

Pharmacology for ferumoxytol
Paragraph IV (Patent) Challenges for FERUMOXYTOL
Tradename Dosage Ingredient NDA Submissiondate
FERAHEME SOLUTION;INTRAVENOUS ferumoxytol 022180 2015-12-04

US Patents and Regulatory Information for ferumoxytol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Sandoz Inc FERUMOXYTOL ferumoxytol SOLUTION;INTRAVENOUS 206604-001 Jan 15, 2021 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ferumoxytol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 ⤷  Free Forever Trial ⤷  Free Forever Trial
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 ⤷  Free Forever Trial ⤷  Free Forever Trial
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 ⤷  Free Forever Trial ⤷  Free Forever Trial
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 ⤷  Free Forever Trial ⤷  Free Forever Trial
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for ferumoxytol

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1169062 2012C/052 Belgium ⤷  Free Forever Trial PRODUCT NAME: FERUMOXYTOL; AUTHORISATION NUMBER AND DATE: EU/1/12/774/001 20120620
1169062 C300558 Netherlands ⤷  Free Forever Trial PRODUCT NAME: FERUMOXYTOL IN IEDERE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/12/774/001-002 20120615
1169062 C01169062/01 Switzerland ⤷  Free Forever Trial PRODUCT NAME: FERUMOXYTOL; REGISTRATION NO/DATE: SWISSMEDIC 62033 17.08.2012
1169062 1290043-7 Sweden ⤷  Free Forever Trial PRODUCT NAME: FERUMOXYTOL; REG. NO/DATE: EU/1/12/774/001 20120615
1169062 92114 Luxembourg ⤷  Free Forever Trial PRODUCT NAME: FERUMOXYTOL
1169062 CA 2012 00050 Denmark ⤷  Free Forever Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Merck
Mallinckrodt
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.